Clinical Trial: Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy

Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Effect of Nerve Growth Factor (Cerebrolysin) Therapy on Neurodevelopment, Sleep Pattern and Quality of Life in Children With Traumatic Brain Injury and Cerebral Palsy

Brief Summary:

Cerebral palsy (CP) is the most frequent cause of motor handicap among children. The economic burden of CP in USA includes $1.18 billion in direct medical costs, $1.05 billion in direct non-medical costs, and an additional $9.24 billion in indirect costs, for a total cost of $11.5 billion or $921,000 average cost per person. Associated disabilities as mental retardation, delayed speech development add psychological burden of the disease on the family as well as economic burden.

Mental retardation is the major problem in children with cerebral palsy. Improving mental development will have a positive effect on quality of life for the child and his family. Treating associated impairments (mental retardation) with Cerebrolysin will improve mental development and quality of life, and will decrease the economic burden in children with cerebral palsy.


Detailed Summary:
Sponsor: Ain Shams University

Current Primary Outcome: neurodevelopment [ Time Frame: 6 months ]

Intelligence quotient (IQ) assessment at base line and after 3 and 6 month of therapy


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Ain Shams University

Dates:
Date Received: April 15, 2014
Date Started: April 2014
Date Completion: April 2016
Last Updated: April 15, 2014
Last Verified: April 2014